Milnacipran

Milnacipran
Top: (1S,2R)-milnacipran (L-milnacipran)
Bottom: (1R,2S)-milnacipran (D-milnacipran)
Left: (1S,2R)-milnacipran (L-milnacipran)
Right: (1R,2S)-milnacipran (D-milnacipran)
Clinical data
Trade namesSavella, others
AHFS/Drugs.comMonograph
MedlinePlusa609016
Pregnancy
category
  • AU: B3
Routes of
administration
By mouth
Drug classSerotonin–norepinephrine reuptake inhibitor (SNRI)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability85%
Protein binding13%
MetabolismHepatic
Elimination half-life6–8 hours
ExcretionRenal
Identifiers
  • (±)-(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1- phenylcyclopropane-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H22N2O
Molar mass246.354 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C(N(CC)CC)[C@@]2(c1ccccc1)[C@@H](CN)C2
  • InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1 checkY
  • Key:GJJFMKBJSRMPLA-HIFRSBDPSA-N checkY
  (verify)

Milnacipran, sold under the brand name Savella among others, is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia, major depressive disorder, and neuropathic pain. In the US, it is solely approved for the treatment of fibromyalgia, even though it is also approved for the treatment of major depressive disorder (but not fibromyalgia) in other countries (e.g., France).